Navigation Links
Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
Date:10/5/2009

SAN DIEGO, Oct. 5 /PRNewswire/ -- Conatus Pharmaceuticals Inc., a privately held, clinical stage company developing a treatment for liver disease associated with Hepatitis C Virus (HCV), announced today that Steven J. Mento, Ph.D., President and Chief Executive Officer, will present at the Montgomery Healthcare Conference being held in Menlo Park, CA, on October 6, 2009. Conatus is one of only 30 companies selected to present to this invitation-only audience of senior-level private equity and venture capital investors and corporate industry executives.

Dr. Mento will provide a corporate overview and highlight Conatus' scientific rationale, progress in clinical development and business development strategy of its lead compound, CTS-1027.

Conatus recently initiated a second Phase 2 clinical trial with its novel drug candidate CTS-1027 for the treatment of liver disease associated with HCV infection. The trial is enrolling patients who have not undergone therapy with approved standard of care treatments. Results from an earlier Phase 2 clinical trial in HCV patients who failed standard of care treatment are expected to be reported later this year.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 has shown to be effective in multiple preclinical models of inflammatory liver disease and HCV infection.

"Preclinical studies suggest that treatment with CTS-1027 has the potential to impact the second phase of HCV inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV-infected cells by uninfected liver cells," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.

SOURCE Conatus Pharmaceuticals


'/>"/>
SOURCE Conatus Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
2. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
3. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
4. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
5. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
6. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
7. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
8. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
9. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
10. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
11. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , Mar 23, 2017 NeuroVive Pharmaceutical ... today announced that the English version of the Annual report ... www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical AB is a ... discovery and development of medicines that preserve mitochondrial integrity and ...
(Date:3/22/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Respiratory care ... 10.9% over the next decade to reach approximately $38.27 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... Under the impetus of the fast-growing ... increased year by year at the CAGR of ... market size will maintain the growth rate of ... billion in 2021, thanks to severe aging, the ... agents and supporting policies. At present, Chinese ...
Breaking Medicine Technology:
(Date:3/23/2017)... New Jersey (PRWEB) , ... March 23, 2017 ... ... developer of herbal-based and non-steroidal skincare products, was awarded as winners of American ... innovation products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... 23, 2017 , ... The Boulevard is honored to host Shriners and Masons ... be located in the Main West Entrance of The Boulevard (in front of JCPenney). ... is necessary and each child with a parent or guardian will be photographed for ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... has selected HealthiPASS, an innovative patient - centric payment system, to expand its ... massive improvements in the patient financial experience. , “At Ogden Clinic, we ...
(Date:3/23/2017)... ... March 23, 2017 , ... “More Corruption”: a simple and strong explanation of the God’s ... the rulers of Heaven was asked by God to write a book about Him. , ... just because I kept my commitment to the Lord God. They have not walked in ...
Breaking Medicine News(10 mins):